Authors:
Borchmann, P
Schnell, R
Knippertz, R
Staak, JO
Camboni, GM
Bernareggi, A
Hubel, K
Staib, P
Schulz, A
Diehl, V
Engert, A
Citation: P. Borchmann et al., Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma, ANN ONCOL, 12(5), 2001, pp. 661-667
Authors:
Manzke, O
Tesch, H
Borchmann, P
Wolf, J
Lackner, K
Gossmann, A
Diehl, V
Bohlen, H
Citation: O. Manzke et al., Locoregional treatment of low-grade B-cell lymphoma with CD3 x CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation, INT J CANC, 91(4), 2001, pp. 508-515
Authors:
Schnell, R
Vitetta, E
Schindler, J
Borchmann, P
Barth, S
Ghetie, V
Hell, K
Drillich, S
Diehl, V
Engert, A
Citation: R. Schnell et al., Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin, LEUKEMIA, 14(1), 2000, pp. 129-135
Authors:
Wickenhauser, C
Borchmann, P
Diehl, V
Scharffetter-Kochanek, K
Citation: C. Wickenhauser et al., Development of IgG lambda multiple myeloma in a patient with cutaneous CD30(+) anaplastic T-cell lymphoma, LEUK LYMPH, 35(1-2), 1999, pp. 201
Authors:
Reiser, M
Schnell, R
Straub, G
Borchmann, P
Wilhelm, M
Ubelacker, R
Wormann, B
Munch, R
Diehl, V
Engert, A
Citation: M. Reiser et al., DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide andetoposide): An effective and well-tolerated new regimen for patients with relapsed lymphoma, LEUK LYMPH, 31(3-4), 1998, pp. 359-366